Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage treatment for the rare muscle weakness disease myasthenia gravis to its R&D pipeline and setting up a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback